Hsbc Holdings PLC Increases Holdings in Evolent Health, Inc $EVH

Key Points

• HSBC Holdings PLC significantly increased its stake in Evolent Health by 94.7%, acquiring an additional 54,186 shares to hold a total of 111,396 shares worth approximately $1,048,000.
• Evolent Health reported a loss of $0.10 earnings per share for the last quarter, missing analysts' expectations and showing a decline in revenue of 31.3% year-over-year.
• Several firms including Piper Sandler and Truist Financial have raised their price targets for Evolent Health, with the consensus target now set at $18.07, indicating a generally positive outlook for the stock.

Hsbc Holdings PLC boosted its holdings in Evolent Health, Inc (NYSE:EVH - Free Report) by 94.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 111,396 shares of the technology company's stock after buying an additional 54,186 shares during the quarter. Hsbc Holdings PLC owned approximately 0.10% of Evolent Health worth $1,048,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of EVH. Brighton Jones LLC purchased a new position in Evolent Health in the fourth quarter valued at $3,927,000. First Trust Advisors LP boosted its stake in Evolent Health by 401.8% in the fourth quarter. First Trust Advisors LP now owns 151,919 shares of the technology company's stock valued at $1,709,000 after acquiring an additional 121,645 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Evolent Health by 19.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,897,443 shares of the technology company's stock valued at $32,595,000 after acquiring an additional 466,225 shares in the last quarter. MetLife Investment Management LLC boosted its stake in Evolent Health by 6.3% in the fourth quarter. MetLife Investment Management LLC now owns 70,915 shares of the technology company's stock valued at $798,000 after acquiring an additional 4,185 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in Evolent Health by 4.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 744,445 shares of the technology company's stock valued at $8,376,000 after acquiring an additional 28,540 shares in the last quarter.

Evolent Health Stock Performance

NYSE:EVH traded down $0.10 during mid-day trading on Wednesday, reaching $9.52. The stock had a trading volume of 869,093 shares, compared to its average volume of 2,676,069. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.01 and a current ratio of 1.01. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -5.90 and a beta of 0.73. Evolent Health, Inc has a twelve month low of $7.06 and a twelve month high of $31.80. The business has a 50 day simple moving average of $10.12 and a 200 day simple moving average of $9.54.

Evolent Health (NYSE:EVH - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The technology company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.20). The firm had revenue of $444.33 million during the quarter, compared to analyst estimates of $459.43 million. Evolent Health had a negative net margin of 5.94% and a positive return on equity of 1.83%. Evolent Health's revenue for the quarter was down 31.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.30 EPS. Evolent Health has set its Q3 2025 guidance at EPS. On average, analysts expect that Evolent Health, Inc will post 0.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on EVH. Piper Sandler upped their price objective on shares of Evolent Health from $16.00 to $18.00 and gave the company an "overweight" rating in a research note on Thursday, August 28th. UBS Group upped their price objective on shares of Evolent Health from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Truist Financial upped their price objective on shares of Evolent Health from $14.00 to $16.00 and gave the company a "buy" rating in a research note on Thursday, July 17th. JMP Securities reiterated a "market outperform" rating and set a $13.00 target price on shares of Evolent Health in a research note on Friday, June 20th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $15.00 target price on shares of Evolent Health in a research note on Tuesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $18.07.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.